NZ627593A - Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof - Google Patents

Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Info

Publication number
NZ627593A
NZ627593A NZ627593A NZ62759313A NZ627593A NZ 627593 A NZ627593 A NZ 627593A NZ 627593 A NZ627593 A NZ 627593A NZ 62759313 A NZ62759313 A NZ 62759313A NZ 627593 A NZ627593 A NZ 627593A
Authority
NZ
New Zealand
Prior art keywords
composition
pyridoxine
release component
pharmaceutically acceptable
phosphate
Prior art date
Application number
NZ627593A
Other languages
English (en)
Inventor
Manon Vranderick
Jean-Luc St-Onge
Christelle Gedeon
Michele Gallo
Éric Gervais
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49004884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ627593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of NZ627593A publication Critical patent/NZ627593A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ627593A 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof NZ627593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601754P 2012-02-22 2012-02-22
PCT/CA2013/050125 WO2013123595A1 (en) 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Publications (1)

Publication Number Publication Date
NZ627593A true NZ627593A (en) 2015-12-24

Family

ID=49004884

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ627593A NZ627593A (en) 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Country Status (25)

Country Link
US (3) US9089489B2 (cg-RX-API-DMAC10.html)
EP (2) EP2787971A4 (cg-RX-API-DMAC10.html)
JP (2) JP5914701B2 (cg-RX-API-DMAC10.html)
KR (1) KR101588259B1 (cg-RX-API-DMAC10.html)
CN (1) CN104136004B (cg-RX-API-DMAC10.html)
AR (2) AR090126A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013224598B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014020186A8 (cg-RX-API-DMAC10.html)
CA (1) CA2848798C (cg-RX-API-DMAC10.html)
CL (1) CL2014001828A1 (cg-RX-API-DMAC10.html)
CY (1) CY1123122T1 (cg-RX-API-DMAC10.html)
DK (1) DK3326611T3 (cg-RX-API-DMAC10.html)
ES (1) ES2809713T3 (cg-RX-API-DMAC10.html)
HK (1) HK1197035A1 (cg-RX-API-DMAC10.html)
HU (1) HUE052301T2 (cg-RX-API-DMAC10.html)
IL (1) IL233644A (cg-RX-API-DMAC10.html)
LT (1) LT3326611T (cg-RX-API-DMAC10.html)
MX (1) MX355912B (cg-RX-API-DMAC10.html)
NZ (1) NZ627593A (cg-RX-API-DMAC10.html)
PL (1) PL3326611T3 (cg-RX-API-DMAC10.html)
PT (1) PT3326611T (cg-RX-API-DMAC10.html)
SG (1) SG11201403931YA (cg-RX-API-DMAC10.html)
TW (1) TWI638657B (cg-RX-API-DMAC10.html)
UY (1) UY34631A (cg-RX-API-DMAC10.html)
WO (1) WO2013123595A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5914701B2 (ja) 2012-02-22 2016-05-11 デュシネイ・インコーポレイテッド ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów
CN103432126A (zh) * 2013-08-05 2013-12-11 北京阜康仁生物制药科技有限公司 一种治疗孕吐的药物组合物
SG11201701448XA (en) * 2014-08-29 2017-03-30 Duchesnay Inc Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP3337480A4 (en) 2015-08-17 2019-05-08 Aequus Pharmaceuticals Inc. TRANSDERMAL ADMINISTRATION OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
EP4035660A1 (en) 2017-10-17 2022-08-03 Synthon B.V. Tablets comprising tamsulosin and solifenacin
RS61368B1 (sr) * 2018-09-27 2021-02-26 Inibsa Ginecologia S A Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
WO2022254277A1 (en) * 2021-05-31 2022-12-08 Maneesh Pharmaceuticals Ltd Extended release composition and its process for the preparation
AU2021225255B1 (en) * 2021-09-03 2022-06-16 Patel, Mihir MR Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.
WO2024180559A1 (en) * 2023-03-01 2024-09-06 Akums Drugs & Pharmaceuticals Limited A stable tablet-in-tablet composition for nausea vomiting in pregnancy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6514481B1 (en) 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
DE60219607T2 (de) 2001-01-09 2007-12-27 Microchips, Inc., Bedford Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
AU2003303288B2 (en) 2002-08-16 2006-12-07 Microchips, Inc. Controlled release device and method
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
ATE424928T1 (de) 2004-09-01 2009-03-15 Microchips Inc Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US9034843B2 (en) 2007-09-14 2015-05-19 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
US9884022B2 (en) * 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
CN103037849A (zh) * 2010-06-22 2013-04-10 安成国际药业股份有限公司 具有减少的食物效应的控释组合物
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
JP5914701B2 (ja) 2012-02-22 2016-05-11 デュシネイ・インコーポレイテッド ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów

Also Published As

Publication number Publication date
CN104136004B (zh) 2018-03-06
US9089489B2 (en) 2015-07-28
BR112014020186A8 (pt) 2017-07-11
MX2014008594A (es) 2015-03-03
EP3326611B1 (en) 2020-05-06
SG11201403931YA (en) 2014-08-28
JP5914701B2 (ja) 2016-05-11
TWI638657B (zh) 2018-10-21
CL2014001828A1 (es) 2014-11-14
US20160374946A1 (en) 2016-12-29
IL233644A (en) 2016-05-31
UY34631A (es) 2013-09-30
TW201334780A (zh) 2013-09-01
BR112014020186A2 (cg-RX-API-DMAC10.html) 2017-06-20
AU2013224598B2 (en) 2015-09-17
HK1197035A1 (en) 2015-01-02
CA2848798C (en) 2014-12-23
EP2787971A4 (en) 2015-04-29
PL3326611T3 (pl) 2020-11-02
KR101588259B1 (ko) 2016-01-25
CA2848798A1 (en) 2013-08-29
EP2787971A1 (en) 2014-10-15
MX355912B (es) 2018-05-04
US9375404B2 (en) 2016-06-28
AR090126A1 (es) 2014-10-22
US9937132B2 (en) 2018-04-10
DK3326611T3 (da) 2020-08-17
JP2016053092A (ja) 2016-04-14
CN104136004A (zh) 2014-11-05
PT3326611T (pt) 2020-08-20
AU2013224598A1 (en) 2014-07-31
US20150366808A1 (en) 2015-12-24
IL233644A0 (en) 2014-08-31
LT3326611T (lt) 2020-08-25
AR122580A2 (es) 2022-09-21
WO2013123595A1 (en) 2013-08-29
ES2809713T3 (es) 2021-03-05
HUE052301T2 (hu) 2021-04-28
EP3326611A1 (en) 2018-05-30
CY1123122T1 (el) 2021-10-29
JP2015508082A (ja) 2015-03-16
KR20140139496A (ko) 2014-12-05
US20140314680A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
MX355912B (es) Formulación de doxilamina y piridoxina y/o sus metabolitos o sales.
WO2014179155A3 (en) Systems and methods for syncronizing multiple electronic devices
HUS000508I2 (hu) Oszilodrosztát vagy gyógyszerészetileg elfogadható sója, beleértve az oszilodrosztát-dihidrogén-foszfátot
WO2014197876A3 (en) Sharing three-dimensional gameplay
IL220786A (en) Multi-synchronous optical sources for tof range detection systems
AU2014338549A8 (en) Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
SG10201805657PA (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
IN2014CN03857A (cg-RX-API-DMAC10.html)
PH12013502325A1 (en) Drug delivery system
WO2012085927A3 (en) Tadalafil compositions
PH12014501408A1 (en) Immediate release multi unit pellet system
SG194162A1 (en) Antihypertensive pharmaceutical composition
PH12015501154A1 (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
PH12012502386A1 (en) Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
MY191347A (en) Composition for the management of nausea and vomiting
MX360047B (es) Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.
PH12017500282A1 (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
TW201613584A (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
MX394413B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma
EP2575457A4 (en) ORAL PHARMACEUTICAL DULOXETIN COMPOSITION
WO2011107921A3 (en) Modified release composition of milnacipran
IN2015DN01463A (cg-RX-API-DMAC10.html)
WO2013095042A3 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
WO2012115446A3 (ko) Ｔ-형 칼슘 채널 길항제로서의 5-(치환된알킬아미노메틸)아이속사졸계 화합물

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20170214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2019 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20171130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20181129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2021 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20200128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2022 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20210119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2023 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20211213

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2024 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20221213

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2025 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20231124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2026 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20241206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2027 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20260210